Table 1.
Characteristics of all participants and participants in the dyspnea group and nondyspnea group
| All participants (n = 367) | Dyspnea (n = 75) | Nondyspnea (n = 292) | p value | |
|---|---|---|---|---|
| Female, n (%) | 150 (40.8) | 53 (70.7) | 97 (33.2) | < 0.001 |
| Age (years), mean (SD) | 15.8 (± 0.4) | 15.7 (±0.48) | 15.8 (±0.4) | 0.45 |
| BMI, mean (SD) | 21.7 (±2.9) | 21.5 (±3.1) | 21.8 (±2.8) | 0.46 |
| Overweight and obesitya, n (%) | 59 (17.3) | 10 (14.2) | 49 (18) | 0.58 |
| Current asthmab, n (%) | 50 (14) | 33 (44) | 17 (6) | < 0.001 |
| Rhinitis, n (%) | 107 (29.9) | 24 (33.3) | 83 (29.2) | 0.56 |
| Wheeze, n (%) | 72 (20.1) | 35 (48.6) | 37 (12.9) | < 0.001 |
| Day time Dyspnea, n (%) | 28 (7.8) | 13 (20.3) | 15 (4.6) | < 0.001 |
| Nocturnal Dyspnea, n (%) | 9 (2.5) | 6 (8.1) | 3 (1) | 0.003 |
| ICSc, n (%) | 28 (7.8) | 16 (22.3) | 12 (4.4) | < 0.001 |
| SABAc, n (%) | 63 (18.3) | 36 (50) | 27 (9.9) | < 0.001 |
| LABAc, n (%) | 10 (2.9) | 4 (6.2) | 6 (2.2) | 0.010 |
| LTRAc, n (%) | 5 (1.5) | 3 (4.5) | 2 (0.7) | 0.054 |
P‐value: Dyspnea versus Non‐dyspnea. BMI, body mass index (kg/m2); ICS, inhaled corticosteroids; SABA, short‐acting β2‐agonists; LABA, long‐acting β2‐agonists; LTRA, leukotriene receptor antagonist.
Available data: All 367 subjects responded to all the questions in the questionnaire except BMI n = 342, physician‐diagnosed asthma n = 357, rhinitis, wheeze, day‐time dyspnea, nocturnal dyspnea and ICS n = 358, SABA n = 345, LABA and LTRA n = 340.
a
Overweight and obesity defined as BMI ≥ 85th percentile.
b
Self‐reported physician‐diagnosed with symptoms and/or medication excluding SABA only.
c
Any use in last three months.